Quantcast
Last updated on April 20, 2014 at 5:20 EDT

Economic Benefit of the HyperQ(TM) Stress Test in the Diagnosis and Management of Coronary Heart Disease Validated in a new Study

June 7, 2010

TEL AVIV, Israel, June 7, 2010 /PRNewswire-FirstCall/ — BSP Biological
Signal Processing Ltd. (http://www.bsp.co.il), develops and markets
innovative systems for non-invasive diagnosis and monitoring of Ischemic
Heart Disease (IHD) based on its proprietary HyperQ(TM) technology. BSP
recently presented the results of a study on the economic and clinical
benefits of the HyperQ(TM) stress test in the diagnosis and management of
coronary heart disease (CHD) at the International Congress on
Electrocardiology on June 4th, 2010.

Analysis of the patient workup for the diagnosis of CHD demonstrated that
the improved clinical accuracy of the HyperQ(TM) compared to standard stress
testing can potentially lead to a reduction of 13% in unnecessary cardiac
imaging tests (750,000 tests annually in the USA), and a significant
reduction in unwarranted angiographies (over 200,000 procedures annually in
the USA) with healthcare savings exceeding $ 1 billion annually.

In addition, analysis of CHD patient care costs demonstrated that the use
of HyperQ(TM) stress test reduces the number of undiagnosed patients and thus
leads to an improvement in cardiac care and the accuracy of diagnosing CHD
patients. Based on published data, routine use of the HyperQ(TM) will reduce
the number of acute cardiac events (including heart attacks), and lower
mortality resulting from CHD while reducing the overall costs to the health
care system.

BSP intends to use this analysis’ results in discussions with US
insurers, aimed at allocating an elevated coverage code for the HyperQ(TM)
procedure. HyperQ(TM) technology and the great economic benefit it offers
correlate perfectly with the current administration’s healthcare reform,
supporting more cost-effective care and reducing unwarranted expensive and
radioactive procedures.

About BSP

Founded in 2000, BSP is dedicated to providing novel, risk free and
highly reliable solutions for the diagnosis and monitoring of cardiovascular
disease. BSP’s proprietary HyperQ(TM) technology is implemented in cardiac
systems that offer accurate, low-cost and risk free cardiac monitoring and
allows, for the first time, an effective diagnosis of ischemic heart disease
in broad populations. BSP is a traded company on the Tel Aviv Stock Exchange
since 2006 (TASE: BSP). The company’s international offices are located in
Tel Aviv, Israel and Rockville, Maryland, USA.

    For more information please contact:
    Dr. Amir Beker, CEO, Biological Signal Processing Ltd.
    amir@bspmedical.com
    Tel. +972-3-6474840

SOURCE BSP – Biological Signal Processing Ltd


Source: newswire